Helicobacter pylori (H. pylori) infection has been reported in more than half of the world human population. It is associated with gastric inflammation and noticeable infiltration of the immune cells to the stomach mucosa by several cytokines secretion. IL-1β, IL-18 have been shown to contribute to H. pylori induced gastritis, but the details of inflammation and association of virulence factors remain unclear. IL-1 cytokine family has a new additional cytokine, Interleukin-33 (IL-33), which is contemplated to have an important role for host defense against microorganisms. H. pylori virulence factors important in gastritis risk are the cag pathogenicity island (cag-PAI) and babA. This study evaluated IL-33 mucosal mRNA expression levels in infected and uninfected patients and its relationship with bacterial virulence factors cagA, babA 2 and type of gastritis. Total RNA was extracted from gastric biopsies of 79 H. pylori-infected patients and 51 H. pylori-negative patients. Mucosal IL-33 mRNA expression levels in gastric biopsies were assessed using real-time PCR. Existence of virulence factors were detected by PCR. IL-33 mRNA expression was significantly higher in biopsies of H. pylori-infected patients compared to H. pylori-uninfected patients (P<0.0001). Also there was a direct relationship between virulence factor bab-A 2 and enhancement in IL-33 mRNA expression. Furthermore, IL-33 mRNA expression level was significantly lower in chronic gastritis patients compared with patients with active gastritis (P<0.001).
infection is associated with gastritis and immune cell infiltration into the gastric mucosa that may lead to chronic gastritis, peptic ulcer and production of pro inflammatory cytokines such as IL-1, IL-8, and TNFα (3, 4) . In recent years, a newly addition to the IL-1 family is IL-33 which has high similarity to IL-18. In contrast to IL-18, IL-33 has anti-inflammatory effects although a TH1 response has been reported (5, 6) . IL-33 is produced as a 30 kD protein which is cleaved by caspase to produce an 18 kD form. IL-33 is highly expressed in the stomach epithelium. However, its gastric function is unknown (5) . IL-33 exists in the nucleus and cytoplasm of macrophages, dendritic cells, fibroblast and endothelial cells (7) . The role of IL-33 and its receptors ST2 "IL-33/ST2" have been identified as crucial to the homeostasis of the epithelial inflammation specially in intestinal epithelium (8) . Patients with ulcerative colitis show increased IL-33 levels in the epithelium of intestine (9) . The ST2 gene relates to the IL-1/TLRs super family which produces four ST2 protein isoforms (10) . In addition, serum ST2 levels are associated with severity of disease that may be a biomarker of disease degree (7, 11) . Some researchers showed high expression level of IL-33 in endothelial cells and cancer cell lines (8, 12) . IL-33 is known to be associated with inflammatory tissue in crohn's disease and rheumatoid arthritis (9) . Although virulence factors may induce gastric inflammation, atrophy, metaplasia and malignancy in the stomach, it has been reported that mucosal levels of proinflammatory cytokines in the infection site with H. pylori are correlated with the various H. pylori virulence factors (13) . This study evaluated IL-33 mucosal mRNA expression levels in infected and uninfected patients and assessed its relationship with bacterial virulence factors cagA, babA 2 and type of gastritis. 
Material & methods

Patients & sampling
Histological examination
Gastric biopsy specimens were merged in 10% 
Statistical analyzes
In statistics, normality tests were used to determine whether a data set is well-modeled by a normal distribution or not. Cytokine expression is presented as means and differences between infected and uninfected groups were analyzed using the Mann-Whitney test. P values<0.05 were considered as significant. more than 35% of gastritis patients were in a chronic phase of H. pylori gastritis (Table 3) .
Results
Genotype analysis
Association between mucosal IL-33 mRNA levels and type of gastritis (Fig. 3 ). 
